IRVINE, Calif., Aug. 14, 2014 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, announced today the market launch of its proprietary handpiece featuring a new 5-millimeter spot size for the Gentle Pro Nd:YAG Laser Series.
The introduction of this new FDA-cleared handpiece expands the functionality of the GentleYAG® Pro and GentleMax® Pro Nd:YAG laser to treat onychomycosis (nail fungus) in addition to its existing capabilities for hair removal and for the treatment of vascular and pigmented lesions.
Onychomycosis is one of the most commonly diagnosed foot conditions, affecting 10-12 percent of the population1. This prevalent and persistent disorder results in thick, jagged nails that can injure surrounding skin, spawning secondary infections and ulcers. Diabetics are especially at risk with a 34 percent chance of developing fungal nail infection and an increased instance of other complications.2 In those age 70 and up, 50 percent are expected to develop onychomycosis.3
Currently a $1.6 billion market in the United States4, the treatment of nail fungus has been challenging. The previous standard of care has been oral antifungal medications, which carry side effects including the potential for hepatotoxicity (chemical driven liver damage) and a high failure rate. Topical treatments have also resulted in limited success due to their inability to properly penetrate the nail.
Laser therapies like Candela's Gentle Pro Nd:YAG Laser allow physicians to treat onychomycosis symptoms locally without the systemic effects of oral medications. All infectious agents, except prions, can be killed by heat, which makes laser therapy an extremely promising new option for onychomycosis sufferers.
With its precision 5 mm handpiece, the Gentle Pro Nd:YAG Laser raises the temperature under the nail to a level that's inhospitable to fungus in order to increase the appearance of clear nails.
"This new indication for the Gentle Pro series puts Syneron at the forefront of technological advancements designed to meet and surpass our physician partners' standards," said Amit Meridor, Chief Executive Officer of Syneron. "The 5 mm handpiece makes our Gentle Pro laser even more valuable for our customers, expanding patient services with one simple addition."
Syneron Medical Ltd. is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch.
Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the U.S. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
For additional information, please visit http://www.syneron-candela.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions, market acceptance of new products, and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical makes with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
Zack Kubow, The Ruth Group email@example.com 646-536-7020
Hugo Goldman, Chief Financial Officer Hugo.Goldman@syneron.com
Syneron Medical, Public Relations firstname.lastname@example.org
Melissa Ben-Yoseph, KELZ PR Melissa@kelzpr.com 646.450.5359
1 David Pariser, MD, Richard K. Scher, MD, Boni Elewski, MD and Phoebe Rich, MD, "Update on Onychomycosis: Effective Strategies for Diagnosis and Treatment," Global Academy for Medical Education, 2013.
2 Doug Brunk, "Lasers Promising for Onychomychosis Treatment," Skin and Allergy News, October 2013, 15.
3 Brunk, 15.
4 Brunk, 15.
SOURCE Syneron Medical Ltd.